Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19

Abstract Hyperactivation of the immune system through obesity and diabetes may enhance infection severity complicated by Acute Respiratory Distress Syndrome (ARDS). The objective was to determine the circulatory biomarkers for macrophage activation at baseline and after serum glucose normalization i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abu Saleh Md Moin, Thozhukat Sathyapalan, Ilhame Diboun, Stephen L. Atkin, Alexandra E. Butler
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/63aade5e782249f39494ff9d1caca99f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:63aade5e782249f39494ff9d1caca99f
record_format	dspace
spelling	oai:doaj.org-article:63aade5e782249f39494ff9d1caca99f2021-12-02T17:05:12ZIdentification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-1910.1038/s41598-021-85760-y2045-2322https://doaj.org/article/63aade5e782249f39494ff9d1caca99f2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85760-yhttps://doaj.org/toc/2045-2322Abstract Hyperactivation of the immune system through obesity and diabetes may enhance infection severity complicated by Acute Respiratory Distress Syndrome (ARDS). The objective was to determine the circulatory biomarkers for macrophage activation at baseline and after serum glucose normalization in obese type 2 diabetes (OT2D) subjects. A case-controlled interventional pilot study in OT2D (n = 23) and control subjects (n = 23). OT2D subjects underwent hyperinsulinemic clamp to normalize serum glucose. Plasma macrophage-related proteins were determined using Slow Off-rate Modified Aptamer-scan plasma protein measurement at baseline (control and OT2D subjects) and after 1-h of insulin clamp (OT2D subjects only). Basal M1 macrophage activation was characterized by elevated levels of M1 macrophage-specific surface proteins, CD80 and CD38, and cytokines or chemokines (CXCL1, CXCL5, RANTES) released by activated M1 macrophages. Two potent M1 macrophage activation markers, CXCL9 and CXCL10, were decreased in OT2D. Activated M2 macrophages were characterized by elevated levels of plasma CD163, TFGβ-1, MMP7 and MMP9 in OT2D. Conventional mediators of both M1 and M2 macrophage activation markers (IFN-γ, IL-4, IL-13) were not altered. No changes were observed in plasma levels of M1/M2 macrophage activation markers in OT2D in response to acute normalization of glycemia. In the basal state, macrophage activation markers are elevated, and these reflect the expression of circulatory cytokines, chemokines, growth factors and matrix metalloproteinases in obese individuals with type 2 diabetes, that were not changed by glucose normalisation. These differences could potentially predispose diabetic individuals to increased infection severity complicated by ARDS. Clinical trial reg. no: NCT03102801; registration date April 6, 2017.Abu Saleh Md MoinThozhukat SathyapalanIlhame DibounStephen L. AtkinAlexandra E. ButlerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Abu Saleh Md Moin Thozhukat Sathyapalan Ilhame Diboun Stephen L. Atkin Alexandra E. Butler Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19
description	Abstract Hyperactivation of the immune system through obesity and diabetes may enhance infection severity complicated by Acute Respiratory Distress Syndrome (ARDS). The objective was to determine the circulatory biomarkers for macrophage activation at baseline and after serum glucose normalization in obese type 2 diabetes (OT2D) subjects. A case-controlled interventional pilot study in OT2D (n = 23) and control subjects (n = 23). OT2D subjects underwent hyperinsulinemic clamp to normalize serum glucose. Plasma macrophage-related proteins were determined using Slow Off-rate Modified Aptamer-scan plasma protein measurement at baseline (control and OT2D subjects) and after 1-h of insulin clamp (OT2D subjects only). Basal M1 macrophage activation was characterized by elevated levels of M1 macrophage-specific surface proteins, CD80 and CD38, and cytokines or chemokines (CXCL1, CXCL5, RANTES) released by activated M1 macrophages. Two potent M1 macrophage activation markers, CXCL9 and CXCL10, were decreased in OT2D. Activated M2 macrophages were characterized by elevated levels of plasma CD163, TFGβ-1, MMP7 and MMP9 in OT2D. Conventional mediators of both M1 and M2 macrophage activation markers (IFN-γ, IL-4, IL-13) were not altered. No changes were observed in plasma levels of M1/M2 macrophage activation markers in OT2D in response to acute normalization of glycemia. In the basal state, macrophage activation markers are elevated, and these reflect the expression of circulatory cytokines, chemokines, growth factors and matrix metalloproteinases in obese individuals with type 2 diabetes, that were not changed by glucose normalisation. These differences could potentially predispose diabetic individuals to increased infection severity complicated by ARDS. Clinical trial reg. no: NCT03102801; registration date April 6, 2017.
format	article
author	Abu Saleh Md Moin Thozhukat Sathyapalan Ilhame Diboun Stephen L. Atkin Alexandra E. Butler
author_facet	Abu Saleh Md Moin Thozhukat Sathyapalan Ilhame Diboun Stephen L. Atkin Alexandra E. Butler
author_sort	Abu Saleh Md Moin
title	Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19
title_short	Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19
title_full	Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19
title_fullStr	Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19
title_full_unstemmed	Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19
title_sort	identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in covid-19
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/63aade5e782249f39494ff9d1caca99f
work_keys_str_mv	AT abusalehmdmoin identificationofmacrophageactivationrelatedbiomarkersinobesetype2diabetesthatmaybeindicativeofenhancedrespiratoryriskincovid19 AT thozhukatsathyapalan identificationofmacrophageactivationrelatedbiomarkersinobesetype2diabetesthatmaybeindicativeofenhancedrespiratoryriskincovid19 AT ilhamediboun identificationofmacrophageactivationrelatedbiomarkersinobesetype2diabetesthatmaybeindicativeofenhancedrespiratoryriskincovid19 AT stephenlatkin identificationofmacrophageactivationrelatedbiomarkersinobesetype2diabetesthatmaybeindicativeofenhancedrespiratoryriskincovid19 AT alexandraebutler identificationofmacrophageactivationrelatedbiomarkersinobesetype2diabetesthatmaybeindicativeofenhancedrespiratoryriskincovid19
_version_	1718381792920076288

Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19

Ejemplares similares